Literature DB >> 26165235

Mouse models for core binding factor leukemia.

D W L Chin1, N Watanabe-Okochi1, C Q Wang1,2, V Tergaonkar2, M Osato1,3,4,5.   

Abstract

RUNX1 and CBFB are among the most frequently mutated genes in human leukemias. Genetic alterations such as chromosomal translocations, copy number variations and point mutations have been widely reported to result in the malfunction of RUNX transcription factors. Leukemias arising from such alterations in RUNX family genes are collectively termed core binding factor (CBF) leukemias. Although adult CBF leukemias generally are considered a favorable risk group as compared with other forms of acute myeloid leukemia, the 5-year survival rate remains low. An improved understanding of the molecular mechanism for CBF leukemia is imperative to uncover novel treatment options. Over the years, retroviral transduction-transplantation assays and transgenic, knockin and knockout mouse models alone or in combination with mutagenesis have been used to study the roles of RUNX alterations in leukemogenesis. Although successful in inducing leukemia, the existing assays and models possess many inherent limitations. A CBF leukemia model which induces leukemia with complete penetrance and short latency would be ideal as a platform for drug discovery. Here, we summarize the currently available mouse models which have been utilized to study CBF leukemias, discuss the advantages and limitations of individual experimental systems, and propose suggestions for improvements of mouse models.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26165235     DOI: 10.1038/leu.2015.181

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  96 in total

1.  Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study.

Authors:  Guido Marcucci; Krzysztof Mrózek; Amy S Ruppert; Kati Maharry; Jonathan E Kolitz; Joseph O Moore; Robert J Mayer; Mark J Pettenati; Bayard L Powell; Colin G Edwards; Lisa J Sterling; James W Vardiman; Charles A Schiffer; Andrew J Carroll; Richard A Larson; Clara D Bloomfield
Journal:  J Clin Oncol       Date:  2005-08-20       Impact factor: 44.544

2.  Runx3 deficiency results in myeloproliferative disorder in aged mice.

Authors:  Chelsia Qiuxia Wang; Lena Motoda; Masanobu Satake; Yoshiaki Ito; Ichiro Taniuchi; Vinay Tergaonkar; Motomi Osato
Journal:  Blood       Date:  2013-06-05       Impact factor: 22.113

3.  Accelerated leukemogenesis by truncated CBF beta-SMMHC defective in high-affinity binding with RUNX1.

Authors:  Yasuhiko Kamikubo; Ling Zhao; Mark Wunderlich; Takeshi Corpora; R Katherine Hyde; Thomas A Paul; Mondira Kundu; Lisa Garrett; Sheila Compton; Gang Huang; Linda Wolff; Yoshiaki Ito; John Bushweller; James C Mulloy; P Paul Liu
Journal:  Cancer Cell       Date:  2010-05-18       Impact factor: 31.743

4.  Cbfb deficiency results in differentiation blocks and stem/progenitor cell expansion in hematopoiesis.

Authors:  C Q Wang; D W L Chin; J Y Chooi; W J Chng; I Taniuchi; V Tergaonkar; M Osato
Journal:  Leukemia       Date:  2014-11-05       Impact factor: 11.528

5.  ETV6/RUNX1 induces reactive oxygen species and drives the accumulation of DNA damage in B cells.

Authors:  Hans-Peter Kantner; Wolfgang Warsch; Alessio Delogu; Eva Bauer; Harald Esterbauer; Emilio Casanova; Veronika Sexl; Dagmar Stoiber
Journal:  Neoplasia       Date:  2013-11       Impact factor: 5.715

6.  Analysis of the role of AML1-ETO in leukemogenesis, using an inducible transgenic mouse model.

Authors:  K L Rhoades; C J Hetherington; N Harakawa; D A Yergeau; L Zhou; L Q Liu; M T Little; D G Tenen; D E Zhang
Journal:  Blood       Date:  2000-09-15       Impact factor: 22.113

7.  Stem cell exhaustion due to Runx1 deficiency is prevented by Evi5 activation in leukemogenesis.

Authors:  Bindya Jacob; Motomi Osato; Namiko Yamashita; Chelsia Qiuxia Wang; Ichiro Taniuchi; Dan R Littman; Norio Asou; Yoshiaki Ito
Journal:  Blood       Date:  2009-12-14       Impact factor: 22.113

8.  AML-1 is required for megakaryocytic maturation and lymphocytic differentiation, but not for maintenance of hematopoietic stem cells in adult hematopoiesis.

Authors:  Motoshi Ichikawa; Takashi Asai; Toshiki Saito; Sachiko Seo; Ieharu Yamazaki; Tetsuya Yamagata; Kinuko Mitani; Shigeru Chiba; Seishi Ogawa; Mineo Kurokawa; Hisamaru Hirai
Journal:  Nat Med       Date:  2004-02-15       Impact factor: 53.440

9.  AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis.

Authors:  T Okuda; J van Deursen; S W Hiebert; G Grosveld; J R Downing
Journal:  Cell       Date:  1996-01-26       Impact factor: 41.582

Review 10.  Point mutations in the RUNX1/AML1 gene: another actor in RUNX leukemia.

Authors:  Motomi Osato
Journal:  Oncogene       Date:  2004-05-24       Impact factor: 9.867

View more
  9 in total

1.  Genetic regulation of the RUNX transcription factor family has antitumor effects.

Authors:  Ken Morita; Kensho Suzuki; Shintaro Maeda; Akihiko Matsuo; Yoshihide Mitsuda; Chieko Tokushige; Gengo Kashiwazaki; Junichi Taniguchi; Rina Maeda; Mina Noura; Masahiro Hirata; Tatsuki Kataoka; Ayaka Yano; Yoshimi Yamada; Hiroki Kiyose; Mayu Tokumasu; Hidemasa Matsuo; Sunao Tanaka; Yasushi Okuno; Manabu Muto; Kazuhito Naka; Kosei Ito; Toshio Kitamura; Yasufumi Kaneda; Paul P Liu; Toshikazu Bando; Souichi Adachi; Hiroshi Sugiyama; Yasuhiko Kamikubo
Journal:  J Clin Invest       Date:  2017-05-22       Impact factor: 14.808

Review 2.  Modeling genetic platelet disorders with human pluripotent stem cells: mega-progress but wanting more on our plate(let).

Authors:  Catriana C Nations; Giulia Pavani; Deborah L French; Paul Gadue
Journal:  Curr Opin Hematol       Date:  2021-09-01       Impact factor: 3.218

Review 3.  Update on acute myeloid leukemia stem cells: New discoveries and therapeutic opportunities.

Authors:  Maximilian Stahl; Tae Kon Kim; Amer M Zeidan
Journal:  World J Stem Cells       Date:  2016-10-26       Impact factor: 5.326

4.  Transcriptional activation of CBFβ by CDK11p110 is necessary to promote osteosarcoma cell proliferation.

Authors:  Yong Feng; Yunfei Liao; Jianming Zhang; Jacson Shen; Zengwu Shao; Francis Hornicek; Zhenfeng Duan
Journal:  Cell Commun Signal       Date:  2019-10-14       Impact factor: 5.712

5.  Detection of residual and chemoresistant leukemic cells in an immune-competent mouse model of acute myeloid leukemia: Potential for unravelling their interactions with immunity.

Authors:  Alexia Mopin; Frédéric Leprêtre; Shéhérazade Sebda; Céline Villenet; Meriem Ben Khoud; Martin Figeac; Bruno Quesnel; Carine Brinster
Journal:  PLoS One       Date:  2022-04-29       Impact factor: 3.240

Review 6.  RUNX1 Mutations in the Leukemic Progression of Severe Congenital Neutropenia.

Authors:  Patricia A Olofsen; Ivo P Touw
Journal:  Mol Cells       Date:  2020-02-29       Impact factor: 5.034

7.  [The prognostic value of cloned genetic mutations in patients with CBFβ-MYH11 fusion-positive acute myeloid leukemia receiving intensive consolidation therapy].

Authors:  J Wang; S L Xue; Z Li; J Q Yu; C Wang; X L Chu; R Han; T Tao; T M Wu; B R Wang; C L Wan; Q C Qiu; X B Bao; D P Wu
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2020-10-14

Review 8.  Mouse Models of Frequently Mutated Genes in Acute Myeloid Leukemia.

Authors:  Sagarajit Mohanty; Michael Heuser
Journal:  Cancers (Basel)       Date:  2021-12-08       Impact factor: 6.639

9.  Inhibition of the RUNX1-CBFβ transcription factor complex compromises mammary epithelial cell identity: a phenotype potentially stabilized by mitotic gene bookmarking.

Authors:  Joshua T Rose; Eliana Moskovitz; Joseph R Boyd; Jonathan A Gordon; Nicole A Bouffard; Andrew J Fritz; Anuradha Illendula; John H Bushweller; Jane B Lian; Janet L Stein; Sayyed K Zaidi; Gary S Stein
Journal:  Oncotarget       Date:  2020-06-30
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.